BioCentury
ARTICLE | Company News

NPS sets Gattex price

January 3, 2013 2:18 AM UTC

NPS Pharmaceuticals Inc. (NASDAQ:NPSP) said it set the annual list price for short bowel syndrome (SBS) drug Gattex teduglutide at $295,000. The company, which plans to launch the Orphan drug in February, said it has identified more than 1,000 patients who are eligible for Gattex and expects to have 200-300 patients on the drug by the end of 2013. NPS said it "expect[s] payers to provide broad access to Gattex" and now estimates peak revenues will be "well in excess of" its previous estimate of $350 million. In late December, FDA approved the analog of glucagon-like peptide-2 (GLP-2) to treat adults with SBS who are dependent on parenteral support. ...